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oVascular calcification has long been a major area of
interest in cardiovascular medicine. A great deal of
data has emerged, ranging from descriptions of the
extent of vascular calcification in ancient Egyptian
mummies to intricate dissections of complex mo-
lecular signaling pathways (1,2). Arguably, the
strongest message to have arisen from the recent
studies appears to be the sobering fact that vascular
calcification is a complex pathobiological process
about which we are only just beginning to gain a
rudimentary understanding. As a prime example,
See page 358
although for a period, there was general agree-
ment that there were 2 principal types of vascular
calcification—intimal (associated with atheroscle-
rosis) and medial (also known as Mönckeberg’s
sclerosis or arteriosclerosis) (3), even this long-
standing classification has now come into question,
with data from patients with renal failure suggesting
that these distinct classifications should be consid-
ered as a continuum (4). Another important new
paradigm to emerge is the so-called vascular calci-
fication paradox, being a robust inverse association
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relevant to the contents of this paper to disclose.etween the degree of bone mineralization and the
egree of vascular calcification (3,5). However, at
he present time, we are far from an adequate
nifying explanation that might explain this recip-
ocal link between vascular and skeletal calcifica-
ion, and a great deal of work remains to be
ndertaken. At the molecular level, unexpected
omplexities have arisen, such as the possibility that
emoval of lipid deposits by the use of statins may
rigger macrophages, osteoclast-like cells, and vas-
ular smooth muscle cells to generate extracellular
atrix and cause vascular calcification (2,6). This
ay explain the paradox of an increase in calcium
core as a parameter of disease, but during the process
f vascular “healing” (6,7). In corroboration, meta-
nalysis data have shown that statin use to reduce or
low vascular calcification is ineffective (8).
Amidst this flurry of activity, MESA (Multi-
thnic Study of Atherosclerosis) has stood as a
teadying reference beacon for almost a decade (9).
n a series of seminal studies, the large and pains-
akingly collected MESA dataset has left an indel-
ble impact on our understanding of coronary artery
alcification (CAC), with a multitude of important
actors shown to influence, or to at least be associ-
ted with, the incidence and progression of CAC
Fig. 1) (9–17). In the process, MESA has raised
he bar for population-level cardiovascular observa-
ional studies, collecting a wealth of parameters
ith a large sample size, thus permitting this rich
uite of publications. In this issue of iJACC, Wong
t al. (17) add to this stable of MESA-derived
apers, focusing on the role of the metabolic syn-
rome (MetS) and diabetes (DM) in CAC devel-
pment and progression. Here, they solve several
ndividually important pieces of the vascular calci-
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368fication puzzle. First, for patients with no CAC at
baseline (as assessed by computed tomography
[CT] scanning), the relative risk of incident CAC
at follow-up scanning (mean of 2.4 years later) was
1.7 to 1.9 for patients with MetS, DM, or both
conditions compared with patients without DM or
MetS. Second, and perhaps most interesting of
their findings, in those with CAC at baseline, there
was a dose-response effect for the progression of
CAC, which in broad terms was least for those
without MetS/DM, intermediate for those with
either MetS or DM, and highest for those with
both conditions. Third, although an association
between CAC progression and clinical cardiovascu-
lar events is already known to exist across all-comers
(DM and non-DM) (18), Wong et al. (17) ex-
tended these data by showing that CAC progres-
sion is associated with subsequent coronary heart
disease events in patients with MetS and DM.
Inevitably, as with any study, there are limita-
tions, one being the lack of consideration of renal
function. Thus, as a possible confounding factor,
patients with DM and/or MetS might be expected
to have a greater prevalence of renal dysfunction,
which may have increased the burden of CAC as a
secondary rather than a primary effect. Also, pa-
tients who experienced a cardiac event before
follow-up scanning were excluded; although their
ce/Ethnicity Heavy Consumption of Hard Liquor
Hypertension
Diabetes/MetS
Microalbuminuria
Adjunctive Medical
Therapies
    Body Mass Index
in Middle Age
Abnormal
Lipoproteins in
Middle Age
ly Determined
on-modifiable
Potentially Modifiable/Treatable
Modifiable
Factors Related to CAC
Shown in MESA
wn to Be Associated With the Incidence and/or Progression of
is whether calciﬁc deposition is a secondary phenomenon to cor-
or all of the factors outlined in the ﬁgure. CAC  coronary artery
ulti-Ethnic Study of Atherosclerosis; MetS  metabolicprogression of CAC is unknown, these patients had amore severe clinical progression of their coronary
rtery disease than others in the study and their
xclusion is a potential source of selection bias;
owever, the number excluded was small (70 of
,662). Finally, as pointed out, the use of statins
ay enhance vascular “healing” but with increased
ascular calcification. The current study does not
rovide such therapeutic information (statin use);
owever, the relatively low and generally equivalent
ipid levels across the patient groups might suggest
imilar use of these agents. Nevertheless, we believe
hat these caveats would appear unlikely to have
ade an appreciable impact on the overall results or
onclusions.
What can we take away from this study? Cer-
ainly, the MESA investigators have now put the
ink between MetS, DM, and CAC beyond ques-
ion. Also, they have demonstrated that even among
atients with MetS/DM, who are already known to
ave an increased risk of coronary heart disease
vents, those with CAC progression are at even
reater risk of these adverse outcomes. This begs
he question of whether clinicians should be per-
orming serial CT scans to identify patients with
etS/DM and significant CAC progression who
ay benefit from particularly aggressive medical
herapy. Although interesting in theory, in the
urrent climate of cost containment and clinical use
ppropriateness criteria, we believe that this use of
esources would be unlikely to gain widespread
cceptance. Indeed, current (2010) appropriate use
riteria classify the repeat use of coronary CT
canning as “inappropriate” in asymptomatic pa-
ients with known coronary artery disease and
revious CT scanning (19). Nevertheless, docu-
entation of rampant progression of CAC in
ccasional selected patients with MetS/DM, renal
ysfunction, or other comorbidities may be of
ssistance in tailoring individual therapeutic regi-
ens, in effect, a form of personalized medicine.
Progress in understanding CAC at the basic and
linical levels has been moving forward at a steady
ace. However, to put this in perspective, in the
oming decades, we are potentially facing a world-
ide cardiovascular health epidemic because it is
redicted that the population will become signifi-
antly older, obesity will increase, and the preva-
ence of DM will increase significantly (20). Given
his, in a small but important way, the data of
ong et al. (17) add to concerns of a looming
ardiovascular health crisis, connecting the dots and
ighlighting that this growing number of peopleWhite Ra
Male Gender
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Genetical
and/or N
     Inflammatory
Biomarkers
Figure 1. Factors Sho
CAC From MESA
What remains unclear
onary disease in some
calciﬁcation; MESA  Mffected with MetS/DM will also be at increased
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369risk of CAC and coronary heart disease events.
Averting this global health crisis has now become a
priority agenda item at the highest levels, including
the United Nations and the Institute of Medicine of
the U.S. National Academy of Sciences (21,22).
Among other things, we need to urgently engage in
targeted research initiatives, to define novel thera-trano R, et al. Risk factors for the
1
1
1
1
1
1
1
1
cium predicts allobesity, DM, and other aspects of this major
cardiovascular health concern (23).
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